Monday Memo

Week of October 5, 2025

Here's what happened in AI this week, without the sensationalism:

1. The Great AI Capital Shift: How Machine Learning Crossed the 50% Threshold in Venture Funding

For the first time in startup history, AI companies are capturing more than half of all venture capital dollars, fundamentally reshaping what gets funded and built.

📊 Hype Score: 4/10

2. AI Reshapes Drug Discovery as MIT and McMaster Map Antibiotic Mechanism with Machine Learning

A breakthrough in AI-assisted drug discovery demonstrates how machine learning can dramatically accelerate understanding of drug mechanisms, while major tech players position for AI's next phase.

📊 Hype Score: 3/10

3. AI Reshapes Drug Discovery as MIT and McMaster Map Antibiotic Mechanism with Machine Learning

A breakthrough collaboration between MIT CSAIL and McMaster University demonstrates how AI can accelerate pharmaceutical research by predicting and mapping antibiotic mechanisms of action.

📊 Hype Score: 3/10

4. AI Industry Shifts: OpenAI's Consumer Focus and Novel Hardware Challenges Nvidia

Major players are repositioning with OpenAI acquiring consumer AI talent while a new hardware startup threatens Nvidia's AI chip dominance.

📊 Hype Score: 4/10

5. AI Research Shifts from Models to Agents: Multi-Agent Systems Show Promise in Drug Discovery and Scientific Research

Recent developments show a clear pivot toward multi-agent AI systems that can collaborate, reason, and conduct autonomous research, with particular breakthroughs in drug discovery and scientific automation

📊 Hype Score: 4/10

View All Briefings →

You're receiving this because you subscribed to AI Without the Hype. We cut through the sensationalism to bring you what actually matters in AI.